Eminent Clinicians and Scientists Expanding Breadth of Cancer
Total Page:16
File Type:pdf, Size:1020Kb
ADVANCES IN ONCOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College Eminent Clinicians and Scientists Expanding Breadth SPRING 2015 of Cancer Expertise at NewYork-Presbyterian Lewis C. Cantley, PhD Meyer Director, Sandra and Edward NewYork-Presbyterian/ NewYork-Presbyterian/ Meyer Cancer Center at Columbia University Medical Center Weill Cornell Medical Center Weill Cornell Medical College/ Ronald P. Stanton Clinical Cancer Experimental Therapeutics Radiation Oncology Program at NewYork-Presbyterian Richard D. Carvajal, MD, is Director of the Silvia C. Formenti, MD, an international expert [email protected] Experimental Therapeutics/Phase 1 Program and in the use of radiation therapy for the treatment Stephen G. Emerson, MD, PhD Melanoma Service in Medical Oncology at NewYork- of cancer, has been Director, Herbert Irving Presbyterian/Columbia University Medical Center. appointed Radiation Comprehensive Cancer Center Prior to joining NewYork-Presbyterian/Columbia, Oncologist-in-Chief at NewYork-Presbyterian/ Dr. Carvajal was Director of Developmental NewYork-Presbyterian/ Columbia University Medical Center [email protected] Therapeutics at Memorial Sloan Kettering Cancer Weill Cornell Medical Center. “Dr. Carvajal Center and Chair of David M. Nanus, MD has spearheaded the newly established Chief, Hematology and Medical Oncology the development of Department of NewYork-Presbyterian/ important treatments Radiation Oncology at Weill Cornell Medical Center that have transformed Weill Cornell Medical Associate Director for Clinical Services, the lives of patients with College. Dr. Formenti Sandra and Edward Meyer Cancer rare cancers,” says Gary has also been named Center at Weill Cornell Medical Dr. Silvia C. Formenti College/Ronald P. Stanton Clinical K. Schwartz, MD, the Associate Director Cancer Program at Chief of Hematology/ of Radiation Oncology NewYork-Presbyterian Oncology and Associate at the Sandra and Edward Meyer Cancer Center at [email protected] Director of the Herbert Weill Cornell Medical College. Gary K. Schwartz, MD Irving Comprehensive A recognized leader in radiation oncology Chief, Hematology and Oncology Dr. Richard D. Carvajal Cancer Center. “With and breast cancer research, Dr. Formenti’s Associate Director, Herbert Irving his experience and groundbreaking work has transformed the Comprehensive Cancer Center talent for innovation, we look forward to his future paradigm in radiation biology, demonstrating NewYork-Presbyterian/ Columbia University Medical Center contributions to patient-centered health care. He brings the efficacy of combining radiotherapy with [email protected] with him a wealth of knowledge on the development immunotherapy to control cancer cell growth in of new agents for patients with a wide range of tumor solid tumors. She has translated preclinical work types, including rare cancers. But, more important, he into clinical trials in metastatic breast cancer, brings the compassion and humanism that characterize lung cancer, and melanoma, and has opened a SAVE THE DATE the doctors at NewYork-Presbyterian/Columbia.” new field of application for radiotherapy, whereby Fourth Annual Update on Dr. Carvajal has extensive clinical expertise localized radiation can be used as an adjuvant to Gastrointestinal Cancers: in melanomas and leadership experience in the immunotherapy of solid tumors and lymphomas. A Multidisciplinary Approach to Screening, Diagnosis, and Treatment development and conduct of early-stage clinical Dr. Formenti, who most recently served as Chair October 30, 2015 trials for patients with advanced cancers and in the of Radiation Oncology at New York University NewYork-Presbyterian/Columbia development of novel therapies for rare cancers. Langone Medical Center, will expand and enhance New York City His work has focused on uncommon, difficult-to- the existing radiation oncology program at Weill For more information: treat cancers, such as uveal melanomas, mucosal Cornell, building upon its already distinguished (212) 304-7813 or [email protected] melanomas, and acral melanomas. His approach reputation of excellence in translational research combines the study of the underlying biology of to better investigate, target, and treat individual cancer with personalized medicine in which genetic patients’ unique cancers. Faculty will investigate profiles of tumors are used to match individual precision medicine approaches to radiation patients with promising therapies. oncology, focusing on combining radiotherapy with (continued on page 2) (continued on page 2) Advances in Oncology Expanding Breadth of Cancer Expertise at NewYork-Presbyterian Experimental Therapeutics (continued from page 1) Radiation Oncology (continued from page 1) “When I started my fellowship in 2004, we were at the early stages immunotherapy and other modifiers of the tumor microenvironment of being able to identify specific genetic driver alterations and match to design advanced treatments and therapies that are tailored to each them with the relevant small molecule inhibitors to achieve clinical patient’s individual tumor. benefit in our patients with cancer,” says Dr. Carvajal. “The past “Dr. Formenti is a tireless crusader for innovation in the field decade has been spent trying to determine how best to utilize these of radiation oncology, and we are delighted that she will be small molecules and other agents targeting various tumor signaling spearheading these efforts for us,” says Steven J. Corwin, MD, pathways. Over the past five years, our ability to develop drugs that CEO of NewYork-Presbyterian Hospital. “Her leadership, expertise specifically manipulate different areas of the immune system and the and commitment to the combined use of tumor radiation and responses that we’ve seen with immunologic checkpoint inhibitors immunotherapy tailored to patient-specific genetics will not only have been dramatic, leading to an acceleration in the development transform cancer care and treatment at NewYork-Presbyterian, but of additional immunologic treatment strategies. The large number will also help us move closer to a cure.” of novel agents in development, both targeted and immunologic in nature, coupled with our ability to achieve a deep molecular “ Combining radiotherapy with immunotherapy is understanding of each patient’s individual tumor and immunological makeup, permits us to really deliver precision medicine and precision exquisitely interdisciplinary work, leveraging the most immunotherapy. By properly matching biology and novel agents, modern integration of pathology, imaging, surgery, we can achieve dramatic clinical benefits even in these early, first-in- medical oncology, and radiation oncology.” man clinical trials. Before 2011, I very rarely used the word cure for – Dr. Silvia C. Formenti patients with advanced melanoma. It was always control. But with some of these new immunologic agents, cure is a very real possibility.” Dr. Carvajal’s research has led to the first positive clinical trials “Combining radiotherapy with immunotherapy is exquisitely of drugs for a number of cancers, including imatinib (Gleevec®), interdisciplinary work, leveraging the most modern integration which was effective in treating patients with melanomas that have a of pathology, imaging, surgery, medical oncology, and radiation mutation in the KIT gene, and selumetinib, which shrank tumors in oncology,” Dr. Formenti says. “The culture and collegiality at half of treated patients with metastatic uveal melanoma, a disease that NewYork-Presbyterian/Weill Cornell and Weill Cornell Medical affects only 2,000 to 3,000 people each year. College provide the best setting to enable these cutting-edge research approaches.” The new Department of Radiation Oncology will empower “ Before 2011, I very rarely used the word cure for patients, scientists to conduct high-impact basic, clinical, and translational for instance, with advanced melanoma. It was always research, and in particular, investigators will engage in radio- control. But with some of these new immunologic agents, biological research, exploring the effects of ionizing radiation on cure is a very real possibility.” tumor and normal tissue with findings translated into preclinical models that can lead to improved, personalized patient care. – Dr. Richard D. Carvajal Funded by the National Institutes of Health, the Department of Defense Breast Cancer Research program, and the Breast Cancer “Ten years ago, limited treatments were available to those with Research Foundation, Dr. Formenti has focused her research endeavors rare forms of cancer,” Stephen G. Emerson, MD, PhD, Director on personalized oncology – designing more effective, targeted of the Herbert Irving Comprehensive Cancer Center. “Since then, treatments tailored to individual patients by combining radiotherapy we have made significant progress in our ability to provide care to with immunotherapy. Her laboratory discovered that this combination these patients. Dr. Carvajal and his colleagues will continue leading therapy overrides cancer’s ability to hijack the normal immune response the effort to find novel therapies for these diseases and to advancing that rejects tumor cells, creating a vaccine against the disease that is personalized medicine.” specific to each individual patient’s tumor. When applied to an Dr. Carvajal has been involved in over 50 clinical trials of novel experimental model of metastatic breast cancer,